Resverlogix (RVX.TO): Update Report 16 January

"Resverlogix (RVX.TO) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. In October 2015, Resverlogix initiated a Phase III clinical trial "BETonMACE" with apabetalone in high-risk CVD patients with type 2 diabetes mellitus and low HDL. The primary endpoint is the time to first occurrence of MACE. Resverlogix has enrolled more than 2,100 of the planned 2,400 patients. An interim analysis is planned after 188 primary MACE events have been adjudicated. We have increased our valuation based on a lower discount rate and an increased LOA for apabetalone in high risk diabetes and CKD patients. With no outstanding long-term debt on its balance sheet, we feel that the risk profile of the company is reduced considerably"

If the link above doesn't work, go to the http://www.leeuwenhoeck.com/ website and you'll find the link to the Resverlogix report on the right side bar.